Treatment Type: Combination Therapy

Dabrafenib (Tafinlar)

Combination Therapy, Targeted TherapyApproved for: NSCLCBiomarker: BRAF Dabrafenib (Tafinlar) is a FDA-approved Targeted Therapy/Combination Therapy for non-small cell lung cancer that has metastasized (NSCLC) with the biomarker BRAF. It is used with trametinib. Dabrafenib is used only in patients...
Read More
|
May 31, 2021
|
Treatment

Durvalumab (Imfinzi)

Combination TherapyApproved for: NSCLC Durvalumab (Imfinzi) is a FDA-approved Combination Therapy for Non-small cell lung cancer (NSCLC). It is used in adults with stage III NSCLC that cannot be removed by surgery and did not get worse after platinum...
Read More
|
May 30, 2021
|
Treatment

Nivolumab (Opdivo/Opdivo Injection)

Combination TherapyApproved for: SCLC Nivolumab (Opdivo/Opdivo Injection) is a FDA-approved CombinationTherapy for Small cell lung cancer (SCLC) that has metastasized. It is used in patients whose cancer got worse after treatment with platinum chemotherapy and at least one other...
Read More
|
May 30, 2021
|
Treatment

Atezolizumab (Tecentriq)

Type of Treatment: Combination TherapyApproved for: NSCLC Atezolizumab (Tecentriq) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that has metastasized. It is used: With bevacizumab, paclitaxel, and carboplatin or paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as first-line...
Read More
|
May 29, 2021
|
Treatment

Atezolizumab (Tecentriq)

Combination TherapyApproved for: SCLC Atezolizumab (Tecentriq) is a FDA-approved treatment for small cell lung cancer (SCLC). It is used with carboplatin and etoposide as first-line therapy in adults with extensive-stage cancer. Related Research News FDA Approves Repotrectinib for Locally...
Read More
|
May 29, 2021
|
Treatment

Atezolizumab (Tecentriq)

Combination TherapyApproved for: NSCLC Atezolizumab (Tecentriq) is a FDA-approved treatment for non-small cell lung cancer (NSCLC). It is used: With bevacizumab, paclitaxel, and carboplatin or paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as first-line therapy in adults with non-squamous non-small...
Read More
|
May 27, 2021
|
Treatment

Durvalumab (Imfinzi)

Combination TherapyApproved for: SCLC Durvalumab (Imfinzi) is a FDA-approved treatment for small cell lung cancer (SCLC) in adults. It is used with etoposide phosphate and either carboplatin or cisplatin as first-line therapy in adults with extensive-stage disease. Related Research...
Read More
|
May 27, 2021
|
Treatment